Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorLi, Weishien_US
dc.date.accessioned2012-07-06T21:32:23Z
dc.date.issued2002en_US
dc.identifier.citationBotanical Drugs: The Next New New Thing? (2002 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8965577
dc.description.abstractWhile herbal medicines hold great promises for treating diseases, they also have serious limitation in their current forms. Currently the regulatory scheme for herbal medicines in the United States is inadequate and it undercuts the incentives for American industry to develop drug products from herbal medicines. This paper argues that FDA should develop a drug model for herbal medicines. This will help both to mainstream herbal medicines in the United States, and to alleviate the production crisis that the American pharmaceutical industry is facing. This paper also assesses FDA~{!/~}s new Draft Guidance for Botanical Drug Products for its incentivizing effects on the industry.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectbotanical drugen
dc.titleBotanical Drugs: The Next New New Thing?en
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-07-06T21:32:23Z
dash.authorsorderedfalse
dash.contributor.affiliatedLi, Weishi


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record